Health ❯ Healthcare ❯ Clinical Research

Clinical Trials

Phase 3 Studies Efficacy Studies Phase 3 Trials Randomized Controlled Trials Phase 2 Trials Patient Outcomes Phase III Trials Real-World Evidence Phase II Trials Patient Access

FDA Approves Auvelity as First Non‑Antipsychotic for Alzheimer’s Agitation

The approval reflects strong relapse‑prevention data from ACCORD‑2 over mixed acute results.

New CAR-T Designs Deliver Low-Dose Remissions and Expose a Senescence Risk

Mayo Clinic AI Flags Pancreatic Cancer on CT Scans Up to Three Years Early

Tirzepatide Linked to Lower Death and Heart Events After PCI and TAVR in New Real-World Analyses

Tempus AI and USC Launch Collaboration to Integrate AI in Precision Medicine

EMA Panel Recommends Redemplo for Familial Chylomicronaemia Syndrome

EU Drug Panel Backs Sanofi’s Cenrifki for Non‑Relapsing SPMS

VDR Gene Variant Tied to 19% Lower Diabetes Risk With High-Dose Vitamin D3

Opus and Viatris Present Phase 3 Phentolamine Data at ASCRS 2026

FDA Grants Accelerated Approval to Kresladi, First Gene Therapy for Severe Pediatric LAD-1

FDA Approves Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes

Health Universe Raises $6 Million Led by Kleiner Perkins to Scale Auditable Healthcare AI

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

Apixaban Cuts Bleeding Versus Rivaroxaban in Venous Thrombosis, NEJM Head-to-Head Trial Finds

Whoop Launches Women’s Health Blood Panel With Cycle Insights

GLP-1 Drugs Tied to Lower Addiction Risk and Fewer Severe Outcomes in Major BMJ Analysis

Early Trial of VIR-5500 Shrinks Tumors in 45% of Advanced Prostate Cancer Cases

Abbott to Commercialize Novo Nordisk’s Semaglutide in India Under Extensior Brand

Cochrane Review Finds No Clear Benefit From Daily Aspirin for Colorectal Cancer Prevention

MRI Signatures Distinguish PSP and CBD, Enabling Smaller, More Feasible Trials